inhaled mAChRs and ADRB2 agonist Ph. I/II candidate in Asthma and COPD discontinued soft drug design from previously disclosed lead MABA J. Med. Chem., July 28, 2022 Chiesi Farmaceutici S.p.A, Parma, IT